Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aranidipine
- Development stage
- Phase 2
- Lead developer
- Maruko Seiyaku
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aranidipine is a dihydropyridine-type calcium channel blocker used primarily for the treatment of hypertension and angina pectoris. It acts by inhibiting the influx of calcium ions through L-type calcium channels in vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Aranidipine also exhibits selective alpha2-adrenoreceptor antagonism, further contributing to its antihypertensive effects. The drug gives rise to two active metabolites (M-1α and M-1β) that retain hypotensive activity. Developed by Maruko Seiyaku and introduced by Taiho, aranidipine was launched in Japan in 1997 under the brand name Sapresta[2][5][7]. Its pharmacological profile includes long-lasting vasodilating actions on both afferent and efferent arterioles[6].
- Brand names
- Sapresta
- Other names
- aranidipine3DMOLSDF3D-SDFPDBSMILESInChI
02
Targets
ADRA2A (α2A)LTCC (Voltage-gated calcium channel (L-type))CaV3 (Caveolin-3)
Beyond the preview
Go deeper on aranidipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aranidipine.